



## **Director of IT**

Kala is an exciting biopharmaceutical company focused on development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. In July of 2017, Kala closed an IPO and recently in October 2017, we submitted a new drug application to the FDA for our product candidate for the treatment of inflammation and pain following ocular surgery, INVELTYS™. Additionally, we are expecting to receive topline results from a Phase 3 clinical program for our KPI-121 0.25% product candidate in patients with dry eye disease by the end of 2017. This is a very exciting time to join Kala.

At just about 40 employees, this is a fantastic opportunity for a capable, resourceful and experienced IT professional to define an IT company strategy as we immerse ourselves into a period of high-growth. Initially, this role will need to be very hands-on as our first in-house IT professional. This individual will own increasing productivity, efficiency and reliability of IT services plus key initiatives in security, communication, and facility expansion. We are looking for someone who is extremely customer-focused with superior problem-solving skills. If you have a strong background in all aspects of IT, and have worked in a highly regulated life sciences organization, you may be the perfect person to fill this position.

Key Responsibilities for this role will include:

- Oversee all technology operations and evaluating them according to overall corporate growth plans
- Analyze complex business needs of the user community and recommend effective technical solutions
- Maintain, manage and deploy networking infrastructure, including VOIP telephony system
- Maintain and manage all IT-related equipment, including the provision and maintenance of computer equipment for all (current, new and separating) on-site and remote employees
- Oversee on-boarding and managing of 3<sup>rd</sup> party software and data systems, and assist with support and trouble-shooting of such software and data systems
- 
- Establish, implement, and monitor company-wide policies and procedures for network security and systems administration, incorporating both industry standard best practices as well as compliance to FDA requirements
- Develop, implement and execute business continuity program

Our ideal candidate will have:

- Bachelors level degree and 10+ years of experience within the IT field in a highly regulated biotech environment, with at least 5 years in a management role
- Prior experience of building and managing both office and laboratory IT environments is required.
- Demonstrated passion and leadership delivering outstanding service to internal IT customers

- Repeated success planning, scaling and deploying systems and network infrastructure with a combination of vendor and internal resources
- Strong track record of providing multiple sites with a secure and stable infrastructure
- Experience supporting or managing VOIP telephony systems
- Experience negotiating and executing corporate wide licensing programs
- Experience implementing IT security including development of information security policies and executing security programs
- Excellent interpersonal skills, including strong oral and written communications with technical and non-technical team members
- High-level of self-motivation; demonstrated success leading a small team supporting a complex and dynamic business

### About Us:

*Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.*